Ipilimumab

Generic Name
Ipilimumab
Brand Names
Yervoy
Drug Type
Biotech
Chemical Formula
-
CAS Number
477202-00-9
Unique Ingredient Identifier
6T8C155666
Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication

Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions
Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
First Line Chemotherapy

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-12-04
Last Posted Date
2023-01-17
Lead Sponsor
Viralytics
Target Recruit Count
50
Registration Number
NCT02307149
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Angeles Clinic & Research Institute, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Advocate Health, SC, Park Ridge, Illinois, United States

and more 8 locations

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-10-31
Last Posted Date
2019-08-28
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
82
Registration Number
NCT02279862
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy

๐Ÿ‡ฉ๐Ÿ‡ช

Universitaetsklinikum Aachen, Aachen, Germany

๐Ÿ‡บ๐Ÿ‡ธ

Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 19 locations

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

First Posted Date
2014-10-27
Last Posted Date
2024-12-16
Lead Sponsor
Ultimovacs ASA
Target Recruit Count
12
Registration Number
NCT02275416
Locations
๐Ÿ‡ณ๐Ÿ‡ด

Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

First Posted Date
2014-10-08
Last Posted Date
2024-08-27
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
39
Registration Number
NCT02259621
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

Johnathan Spicer, Montrรฉal, Quebec, Canada

๐Ÿ‡บ๐Ÿ‡ธ

Johns Hopkins at Bayview Medical Center, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 2 locations

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

First Posted Date
2014-09-15
Last Posted Date
2020-11-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
143
Registration Number
NCT02239900
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

YERVOYยฎ Risk Minimization Tool Effectiveness Evaluation Survey

Completed
Conditions
Interventions
First Posted Date
2014-08-25
Last Posted Date
2015-12-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
158
Registration Number
NCT02224768
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Local Institution, St. Ives, Cambridgeshire, United Kingdom

๐Ÿ‡บ๐Ÿ‡ธ

Bristol-Myers Squibb, Princeton, New Jersey, United States

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2014-08-20
Last Posted Date
2020-05-11
Lead Sponsor
NYU Langone Health
Target Recruit Count
39
Registration Number
NCT02221739
Locations
๐Ÿ‡บ๐Ÿ‡ธ

NYU Clinical Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

NYU Langone Medical Center, Tisch Hospital, New York, New York, United States

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

First Posted Date
2014-08-06
Last Posted Date
2017-07-21
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT02210104
ยฉ Copyright 2024. All Rights Reserved by MedPath